Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNLX NYSE:IKT NASDAQ:IMRX NASDAQ:SHLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNLXGenelux$3.33-5.7%$3.32$1.95▼$5.89$125.77M-0.3291,990 shs101,063 shsIKTInhibikase Therapeutics$1.80-2.2%$1.78$1.12▼$4.20$134.13M0.91188,350 shs71,026 shsIMRXImmuneering$5.75+2.7%$3.90$1.10▼$6.18$208.84M0.43872,736 shs376,252 shsSHLTSHL Telemedicine$2.05$2.05$1.85▼$4.45$33.61M0.1111,919 shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNLXGenelux0.00%-11.90%-5.13%+35.92%+53.46%IKTInhibikase Therapeutics0.00%-4.76%+18.42%-12.20%+28.57%IMRXImmuneering0.00%+17.59%+70.62%+207.49%+418.02%SHLTSHL Telemedicine0.00%0.00%0.00%0.00%-46.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNLXGenelux1.4395 of 5 stars3.52.00.00.02.30.00.0IKTInhibikase Therapeutics1.9991 of 5 stars3.32.00.00.03.70.00.6IMRXImmuneering3.4407 of 5 stars3.34.00.00.01.95.00.6SHLTSHL TelemedicineN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNLXGenelux 3.00Buy$20.33510.61% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50261.11% UpsideIMRXImmuneering 2.60Moderate Buy$13.00126.09% UpsideSHLTSHL Telemedicine 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SHLT, GNLX, IKT, and IMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.008/14/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.007/23/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/18/2025IMRXImmuneeringMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.006/18/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/18/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/5/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNLXGenelux$10K12,577.41N/AN/A$0.76 per share4.38IKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AIMRXImmuneering$320K652.63N/AN/A$1.33 per share4.32SHLTSHL Telemedicine$55.94M0.60$0.04 per share54.03$5.21 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNLXGenelux-$29.87M-$0.86N/AN/AN/AN/A-107.47%-83.14%11/13/2025 (Estimated)IKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/AIMRXImmuneering-$61.04M-$1.89N/AN/AN/AN/A-146.28%-117.22%11/12/2025 (Estimated)SHLTSHL Telemedicine-$7.06MN/A0.00∞N/AN/AN/AN/A9/24/2025 (Estimated)Latest SHLT, GNLX, IKT, and IMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025IMRXImmuneering-$0.40-$0.40N/A-$0.40N/AN/A8/7/2025Q2 2025GNLXGenelux-$0.22-$0.20+$0.02-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNLXGeneluxN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ASHLTSHL TelemedicineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNLXGeneluxN/A4.184.18IKTInhibikase TherapeuticsN/A0.850.85IMRXImmuneeringN/A3.703.70SHLTSHL Telemedicine0.192.171.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNLXGenelux37.33%IKTInhibikase Therapeutics3.81%IMRXImmuneering67.65%SHLTSHL Telemedicine20.11%Insider OwnershipCompanyInsider OwnershipGNLXGenelux8.80%IKTInhibikase Therapeutics7.30%IMRXImmuneering22.90%SHLTSHL TelemedicineN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNLXGenelux1037.77 million34.45 millionNot OptionableIKTInhibikase Therapeutics674.52 million66.18 millionNot OptionableIMRXImmuneering6036.32 million28.00 millionNot OptionableSHLTSHL Telemedicine58316.39 millionN/ANot OptionableSHLT, GNLX, IKT, and IMRX HeadlinesRecent News About These CompaniesSHL Telemedicine ADR Stock Price HistoryJune 20, 2025 | investing.comSHL Telemedicine Clarifies Voting Process for May 2025 AGMMay 20, 2025 | tipranks.comSHL Telemedicine to Delist ADRs from Nasdaq to Cut CostsMarch 11, 2025 | tipranks.comSHLT SHL Telemedicine Ltd.March 6, 2025 | seekingalpha.comSHL Telemedicine Ltd (SHLTN)January 23, 2025 | investing.comSHL Telemedicine (NASDAQ:SHLT) Stock Quotes, Forecast and News SummaryDecember 18, 2024 | benzinga.comDocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular CareDecember 18, 2024 | businesswire.comSHL Telemedicine (NASDAQ:SHLT) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comSHL Telemedicine to Appoint David Arnon as CEO of SHL TelemedicineJuly 29, 2024 | 01net.it0SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli ActivityJune 20, 2024 | businesswire.comSHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood TestMay 21, 2024 | businesswire.comSHL Telemedicine Ltd ADR - NewMay 17, 2024 | morningstar.comMSHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft LaunchMay 16, 2024 | finance.yahoo.comSHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft LaunchMay 16, 2024 | businesswire.comSHL Telemedicine Ltd.: SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical MilestonesApril 17, 2024 | finanznachrichten.deSHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical MilestonesApril 17, 2024 | finance.yahoo.comSHL Telemedicine Ltd. (SHLT)April 16, 2024 | finance.yahoo.comTelehealth clinical trial cuts hospital cardiac readmissions by 76%April 11, 2024 | msn.comImperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient CareApril 11, 2024 | finance.yahoo.comImperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post-ACS Patient CareApril 11, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSHLT, GNLX, IKT, and IMRX Company DescriptionsGenelux NASDAQ:GNLX$3.33 -0.20 (-5.67%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.32 0.00 (-0.15%) As of 08/29/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Inhibikase Therapeutics NYSE:IKT$1.80 -0.04 (-2.17%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.80 0.00 (0.00%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Immuneering NASDAQ:IMRX$5.75 +0.15 (+2.68%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.68 -0.07 (-1.13%) As of 08/29/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.SHL Telemedicine NASDAQ:SHLTSHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use. It offers its telemedicine services and devices to subscribers using electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was incorporated in 1986 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
